BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $91.00 to $89.00. They now have a "hold" rating on the stock.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Global Cell and Gene Therapies in Hemophilia A & B Analysis Report 2024: Market to Reach $2.2 Billion by 2029 - Major Players Are Expected To Intensify Competition [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Citigroup Inc. from $94.00 to $91.00. They now have a "neutral" rating on the stock.